589 related articles for article (PubMed ID: 16461051)
1. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation.
Mukherjee R; Herron AR; Lowry AS; Stroud RE; Stroud MR; Wharton JM; Ikonomidis JS; Crumbley AJ; Spinale FG; Gold MR
Am J Cardiol; 2006 Feb; 97(4):532-7. PubMed ID: 16461051
[TBL] [Abstract][Full Text] [Related]
2. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation.
Xu J; Cui G; Esmailian F; Plunkett M; Marelli D; Ardehali A; Odim J; Laks H; Sen L
Circulation; 2004 Jan; 109(3):363-8. PubMed ID: 14732752
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation.
Anné W; Willems R; Roskams T; Sergeant P; Herijgers P; Holemans P; Ector H; Heidbüchel H
Cardiovasc Res; 2005 Sep; 67(4):655-66. PubMed ID: 15913581
[TBL] [Abstract][Full Text] [Related]
4. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
Yang YJ; Zhang X; Zhu WL; Huang Y
Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324
[TBL] [Abstract][Full Text] [Related]
5. Decreased plasminogen activator inhibitor and tissue metalloproteinase inhibitor expression may promote increased metalloproteinase activity with increasing duration of human atrial fibrillation.
Gramley F; Lorenzen J; Plisiene J; Rakauskas M; Benetis R; Schmid M; Autschbach R; Knackstedt C; Schimpf T; Mischke K; Gressner A; Hanrath P; Kelm M; Schauerte P
J Cardiovasc Electrophysiol; 2007 Sep; 18(10):1076-82. PubMed ID: 17655664
[TBL] [Abstract][Full Text] [Related]
6. [Clinical on molecular basis of atrial fibrosis in patients with atrial fibrillation investigation].
Ke D; Xu CX; Lin YZ; Zhang JC; Chen L; Lin LF; Hu XZ
Zhonghua Xin Xue Guan Bing Za Zhi; 2005 May; 33(5):459-63. PubMed ID: 15932710
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases in rapid atrial pacing-induced atrial fibrillation.
Chen CL; Huang SK; Lin JL; Lai LP; Lai SC; Liu CW; Chen WC; Wen CH; Lin CS
J Mol Cell Cardiol; 2008 Dec; 45(6):742-53. PubMed ID: 18692064
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase inhibition attenuates atrial remodeling and vulnerability to atrial fibrillation in a canine model of heart failure.
Moe GW; Laurent G; Doumanovskaia L; Konig A; Hu X; Dorian P
J Card Fail; 2008 Nov; 14(9):768-76. PubMed ID: 18995182
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation.
Nakano Y; Niida S; Dote K; Takenaka S; Hirao H; Miura F; Ishida M; Shingu T; Sueda T; Yoshizumi M; Chayama K
J Am Coll Cardiol; 2004 Mar; 43(5):818-25. PubMed ID: 14998623
[TBL] [Abstract][Full Text] [Related]
10. Extracellular matrix remodeling attenuated after experimental postinfarct left ventricular aneurysm repair.
Hsu CP; Huang CY; Wang JS; Sun PC; Shih CC
Ann Thorac Surg; 2008 Oct; 86(4):1243-9. PubMed ID: 18805169
[TBL] [Abstract][Full Text] [Related]
11. Effect of matrix metalloproteinase and their inhibitors on atrial myocardial structural remodeling.
Wang W; Zhang HT; Yang XL
J Cardiovasc Med (Hagerstown); 2013 Apr; 14(4):265-9. PubMed ID: 22929563
[TBL] [Abstract][Full Text] [Related]
12. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure.
Wilson EM; Gunasinghe HR; Coker ML; Sprunger P; Lee-Jackson D; Bozkurt B; Deswal A; Mann DL; Spinale FG
J Card Fail; 2002 Dec; 8(6):390-8. PubMed ID: 12528092
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
[TBL] [Abstract][Full Text] [Related]
14. [Changes in gelatinases expression and activity in human atria during atrial fibrillation].
Ke D; Xu CX; Zhang JC; Chen L; Lin YZ; Lin LF; Hu XZ
Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Feb; 33(2):137-42. PubMed ID: 15924808
[TBL] [Abstract][Full Text] [Related]
15. [Role of matrix metalloproteinase and tissue inhibitor of metalloproteinase in atrial structural remodeling in patients with atrial fibrillation].
Wang W; Wu PS; Yang XL
Nan Fang Yi Ke Da Xue Xue Bao; 2010 May; 30(5):1160-2. PubMed ID: 20501421
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression.
Polyakova V; Hein S; Kostin S; Ziegelhoeffer T; Schaper J
J Am Coll Cardiol; 2004 Oct; 44(8):1609-18. PubMed ID: 15489093
[TBL] [Abstract][Full Text] [Related]
17. Extracellular degradative pathways in myocardial remodeling and progression to heart failure.
Spinale FG; Gunasinghe H; Sprunger PD; Baskin JM; Bradham WC
J Card Fail; 2002 Dec; 8(6 Suppl):S332-8. PubMed ID: 12555141
[TBL] [Abstract][Full Text] [Related]
18. Novel approaches to retard ventricular remodeling in heart failure.
Spinale FG
Eur J Heart Fail; 1999 Mar; 1(1):17-23. PubMed ID: 10937974
[TBL] [Abstract][Full Text] [Related]
19. [Effects of matrix metalloproteinase-9 and tissue inhibitor-1 of metalloproteinase expression on atrial structural remodeling during chronic atrial fibrillation].
Zhu H; Zhang W; Guo CH; Zhang G; Zhang WD; Zhong M; Yang GR; Ge ZM; Zhang Y
Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(1):45-8. PubMed ID: 15808077
[TBL] [Abstract][Full Text] [Related]
20. Cardiac remodeling and failure From molecules to man (Part II).
Fedak PW; Verma S; Weisel RD; Li RK
Cardiovasc Pathol; 2005; 14(2):49-60. PubMed ID: 15780796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
